- Home
- MGNX
MGNX
MacroGenics Inc.
as 04-18-2025 1:39pm EST
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | Rockville |
| Market Cap: | 70.3M | IPO Year: | 2013 |
| Target Price: | $6.83 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Hold | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.99 - $17.24 | Next Earning Date: | 05-08-2025 |
| Revenue: | $149,962,000 | Revenue Growth: | 155.26% |
| Revenue Growth (this year): | -74.54% | Revenue Growth (next year): | 80.86% |
Stock Insider Trading Activity of MacroGenics Inc. (MGNX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Smith Beth Ann | MGNX | VP, Controller & Treasurer | Feb 15 '25 | Sell | $2.56 | 423 | $1,082.88 | 9,532 |
Latest MacroGenics Inc. News
MGNX Breaking Stock News: Dive into MGNX Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
4 Medical Product Stocks to Buy From a Challenging Industry
Simply Wall St.
9 days ago
908 Devices Leads These 3 Penny Stocks To Consider
Zacks
16 days ago
MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Clinical Trials Arena
a month ago
MacroGenics axes ADC drug following Phase II failure in prostate cancer
GuruFocus.com
a month ago
Macrogenics Inc (MGNX) Q4 2024: Everything You Need to Know Ahead of Earnings
Thomson Reuters StreetEvents
a month ago
Q4 2024 MacroGenics Inc Earnings Call
GuruFocus.com
a month ago
Macrogenics Inc (MGNX) Q4 2024 Earnings Call Highlights: Revenue Surge Amid Rising Expenses
Motley Fool
a month ago
MacroGenics (MGNX) Q4 2024 Earnings Call Transcript
Compare MGNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MGNX MacroGenics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.